A Study in Participants With Moderate to Severe Psoriasis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01107457
First received: April 14, 2010
Last updated: September 15, 2014
Last verified: September 2014

April 14, 2010
September 15, 2014
April 2010
January 2011   (final data collection date for primary outcome measure)
  • Proportion of Participants who achieve a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) from Baseline to 12 Week Endpoint [ Time Frame: Baseline, 12 Weeks ] [ Designated as safety issue: No ]
  • Percentage of PASI Improvement from Baseline to 12 Week endpoint [ Time Frame: Baseline, 12 Weeks ] [ Designated as safety issue: No ]
  • Proportion of Patients who achieve a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) from baseline to 16 week endpoint [ Time Frame: Baseline, 16 Weeks ] [ Designated as safety issue: No ]
  • Percentage of PASI improvement from baseline to 16 week endpoint [ Time Frame: Baseline, 16 Weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01107457 on ClinicalTrials.gov Archive Site
  • Static Physician's Global Assessment (sPGA) score up to 240 Weeks [ Time Frame: Baseline, up to 240 Weeks ] [ Designated as safety issue: No ]
  • Incidence of Treatment Emergent Adverse Events up to 264 Weeks [ Time Frame: Baseline, up to 264 Weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in 16-item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Patient Global Assessment (PatGA) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Pain Visual Analog scale (VAS) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Medical Outcomes Study Sleep Scale (MOS-S) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Psoriasis Medical Care Resource Utilization (PMRU) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAIQ) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Medical Outcomes Study Short-Form 36 (SF-36) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline up to 240 Weeks in Nail Psoriasis Severity Index (NAPSI) in Participants with Nail Psoriasis [ Time Frame: Baseline, up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline up to 240 Weeks in Scalp Psoriasis Severity Index (SPSI) in Participants with Scalp Psoriasis [ Time Frame: Baseline, up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline up to 240 Weeks in Palmoplantar Psoriasis Severity Index (PPSI) in Participants with Palmoplantar Psoriasis [ Time Frame: Baseline, up to 240 Weeks ] [ Designated as safety issue: No ]
  • Plasma Concentrations of ixekizumab from Baseline through 32 Weeks [ Time Frame: Baseline through 32 Weeks ] [ Designated as safety issue: No ]
  • Change in PASI Score from Baseline up to Week 240 [ Time Frame: Baseline, up to 240 Weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 12 Weeks, 20 Weeks, 32 Weeks, and up to 240 Weeks ] [ Designated as safety issue: No ]
  • Proportion of Participants who achieve a 75% Improvement in the Psoriasis Area and Severity Index (PASI 75) from Baseline through 32 Weeks [ Time Frame: Baseline through 32 Weeks ] [ Designated as safety issue: No ]
  • Percentage of PASI Improvement from Baseline through 32 Weeks [ Time Frame: Baseline through 32 Weeks ] [ Designated as safety issue: No ]
  • Proportion of Participants with a Static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) with at least a 2 point Improvement from Baseline through 32 Weeks [ Time Frame: Baseline through 32 Weeks ] [ Designated as safety issue: No ]
  • static Physician's Global Assessment (sPGA) score through 32 weeks [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
  • Incidence of treatment emergent adverse events through 32 weeks [ Time Frame: Baseline, through 32 Weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline, at 8, 16 and 32 weeks in Hospital Anxiety and Depression (HADS) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline at 8, 16 and 32 weeks in 16-item Quick Inventory of Depressive Symptoms- Self Rated (QIDS-SR16) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Patient Global Assessment (PatGA) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Pain Visual Analog scale (VAS) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Medical Outcomes Study Sleep Scale (MOS-S) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Psoriasis Medical Care Resource Utilization (PMRU) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Work Productivity and Activity Impairment Questionnaire (WPAIQ) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Medical Outcomes Study Short-Form 36 (SF-36) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline through 32 weeks in Nail Psoriasis Severity Index (NAPSI) in patients with nail psoriasis [ Time Frame: Baseline, through 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline through 32 weeks in Scalp Psoriasis Severity Index (SPSI) in patients with scalp psoriasis [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
  • Change from baseline through 32 weeks in Palmoplantar Psoriasis Severity Index (PPASI) in patients with palmoplantar psoriasis [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
  • Plasma Concentrations of LY2439821 from baseline through 32 weeks [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
  • Change in PASI score from baseline through week 32 [ Time Frame: Baselilne, through 32 Weeks ] [ Designated as safety issue: No ]
  • Change from baseline, at 8, 16 and 32 weeks in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 8 Weeks, 16 Weeks, 32 Weeks ] [ Designated as safety issue: No ]
  • Proportion of Patients who achieve a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) from baseline through 32 weeks [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
  • Percentage of PASI improvement from baseline through 32 weeks [ Time Frame: Baseline, through 32 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study in Participants With Moderate to Severe Psoriasis
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

The primary purpose for this study is to help answer the following research questions

  • The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
  • Whether ixekizumab can help participants with Psoriasis.
  • How much ixekizumab should be given to participants.

The study is a Phase 2 study with 2 parts. Part A is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging design and Part B is an optional, open label extension design. Approximately 125 participants will be randomized to 1 of 4 ixekizumab groups or to placebo (approximately 25 participants per group) in Part A. Participants will be evaluated for treatment efficacy and the primary endpoint will be evaluated at week 12. Between week 20 and week 32, participants with a less than 75% improvement in their Psoriasis Area and Severity Index (PASI) score compared to baseline will be eligible to begin Part B. Participants in Part B will receive subcutaneous (SC) injections of ixekizumab 120 milligrams (mg) every 4 weeks through week 236. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236. Participants who complete both Part A and B have a total study participation of up to approximately 240 to 264 weeks.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psoriasis
  • Biological: ixekizumab
    Administered subcutaneously
    Other Name: LY2439821
  • Drug: Placebo
    Administered subcutaneously
  • Experimental: 10 mg ixekizumab

    Part A:

    Administered 10 mg ixekizumab SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
  • Experimental: 25 mg ixekizumab

    Part A:

    Administered 25 mg ixekizumab SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
  • Experimental: 75 mg ixekizumab

    Part A:

    Administered 75 mg ixekizumab SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
  • Experimental: 150 mg ixekizumab

    Part A:

    Administered 150 mg ixekizumab SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
  • Placebo Comparator: Placebo

    Part A:

    Administered on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Interventions:
    • Biological: ixekizumab
    • Drug: Placebo
  • Experimental: 120 mg ixekizumab

    Part B: (optional)

    Administered 120 mg ixekizumab SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
  • Experimental: 80 mg ixekizumab

    Part B: (optional)

    Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab every 4 weeks through Week 236.

    Intervention: Biological: ixekizumab
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
125
July 2016
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria Common to Both Part A and B:

  • You must have active plaque psoriasis covering at least 10% body surface area and a PASI score of 12
  • You are a candidate for systemic therapy
  • You have a sPGA score of at least 3 at screening and at randomization

Inclusion Criterion Specific to Part B

  • You have completed the treatment period for part A (week 20)

Exclusion Criteria Common to Both Part A and B:

  • You have pustular, erythrodermic and/or guttate forms of psoriasis
  • You have had a clinically significant flare of psoriasis during the 12 weeks prior to study entry
  • You are or recently used any biologic agent/monoclonal antibody within the following washout periods: etanercept >28 days, infliximab or adalimumab >56 days, alefacept >60 days, ustekinumab >8 months, or any other biologic agent/monoclonal antibody >5 half-lives prior to baseline
  • You have received systemic psoriasis therapy (such as psoralen and ultraviolet A [PUVA] light therapy, cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine) or phototherapy (including ultraviolet B or self-treatment with tanning beds) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization (exception: class 6 [mild, such as desonide] or 7 [least potent, such as hydrocortisone] topical steroids will be permitted for use limited to the face, axilla, and/or genitalia)
  • You have donated more than 500 mL of blood within the last month
  • You have another serious disorder or illness
  • You have suffered a serious bacterial infection (for example, pneumonia, and cellulitis) within the last 3 months
  • You have a history of uncontrolled high blood pressure
  • You have clinical laboratory test results at entry that are outside the normal reference range
  • You are currently participating in or were discontinued within the last 30 days from another clinical trial involving an investigational drug
  • You are a woman who is lactating or breast feeding
  • If you are a woman and you could become pregnant during this study, you must talk to the study doctor about the birth control that you will use to avoid getting pregnant during the study
  • If you are a post menopausal woman, you must be at least 45 years of age and have not menstruated for the last 12 months
  • If you are a woman between 40-45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, you must have an additional blood test to see if you can participate
  • If you are a male, you must agree to reduce the risk of your female partner becoming pregnant during the study

Exclusion Criteria Specific to B:

  • If you experienced a Serious Adverse Event during Part A considered possibly related to ixekizumab
  • If you experienced an Adverse Event during Part A that the study doctor believes ixekizumab treatment could cause you harm
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Denmark
 
NCT01107457
12060, I1F-MC-RHAJ
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP